CA2241941C - Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis - Google Patents
Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis Download PDFInfo
- Publication number
- CA2241941C CA2241941C CA002241941A CA2241941A CA2241941C CA 2241941 C CA2241941 C CA 2241941C CA 002241941 A CA002241941 A CA 002241941A CA 2241941 A CA2241941 A CA 2241941A CA 2241941 C CA2241941 C CA 2241941C
- Authority
- CA
- Canada
- Prior art keywords
- feline
- interferon
- omega
- therapeutic agent
- cat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 94
- 108010050904 Interferons Proteins 0.000 title claims abstract description 94
- 229940079322 interferon Drugs 0.000 title claims abstract description 91
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 47
- 241000282324 Felis Species 0.000 title abstract description 64
- 201000008937 atopic dermatitis Diseases 0.000 title abstract description 27
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract description 26
- 230000009385 viral infection Effects 0.000 title description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 46
- 208000003265 stomatitis Diseases 0.000 claims abstract description 28
- 241000282326 Felis catus Species 0.000 claims abstract description 24
- 230000001684 chronic effect Effects 0.000 claims abstract description 19
- 208000007502 anemia Diseases 0.000 claims abstract description 18
- 230000003203 everyday effect Effects 0.000 claims abstract description 8
- 241000713800 Feline immunodeficiency virus Species 0.000 claims abstract 14
- 230000037396 body weight Effects 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 241000255789 Bombyx mori Species 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 238000007670 refining Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 28
- 238000002560 therapeutic procedure Methods 0.000 abstract description 25
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 12
- 108010054147 Hemoglobins Proteins 0.000 description 12
- 230000036528 appetite Effects 0.000 description 12
- 235000019789 appetite Nutrition 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003270 steroid hormone Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000005534 hematocrit Methods 0.000 description 7
- 229940047124 interferons Drugs 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 208000006339 Caliciviridae Infections Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000004159 blood analysis Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003978 infusion fluid Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PSBJZLMFFTULDX-IXOXFDKPSA-N Phe-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N)O PSBJZLMFFTULDX-IXOXFDKPSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940105596 baytril Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- XMIAMUXIMWREBJ-HERUPUMHSA-N Ala-Trp-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XMIAMUXIMWREBJ-HERUPUMHSA-N 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- OTUQSEPIIVBYEM-IHRRRGAJSA-N Arg-Asn-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OTUQSEPIIVBYEM-IHRRRGAJSA-N 0.000 description 1
- VNFWDYWTSHFRRG-SRVKXCTJSA-N Arg-Gln-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O VNFWDYWTSHFRRG-SRVKXCTJSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- QHAJMRDEWNAIBQ-FXQIFTODSA-N Asp-Arg-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O QHAJMRDEWNAIBQ-FXQIFTODSA-N 0.000 description 1
- MFTVXYMXSAQZNL-DJFWLOJKSA-N Asp-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)O)N MFTVXYMXSAQZNL-DJFWLOJKSA-N 0.000 description 1
- GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
- SFJUYBCDQBAYAJ-YDHLFZDLSA-N Asp-Val-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SFJUYBCDQBAYAJ-YDHLFZDLSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- OJQJUQUBJGTCRY-WFBYXXMGSA-N Cys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CS)N OJQJUQUBJGTCRY-WFBYXXMGSA-N 0.000 description 1
- XABFFGOGKOORCG-CIUDSAMLSA-N Cys-Asp-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XABFFGOGKOORCG-CIUDSAMLSA-N 0.000 description 1
- VKAWJBQTFCBHQY-GUBZILKMSA-N Cys-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N VKAWJBQTFCBHQY-GUBZILKMSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GURIQZQSTBBHRV-SRVKXCTJSA-N Gln-Lys-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GURIQZQSTBBHRV-SRVKXCTJSA-N 0.000 description 1
- LUGUNEGJNDEBLU-DCAQKATOSA-N Gln-Met-Arg Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LUGUNEGJNDEBLU-DCAQKATOSA-N 0.000 description 1
- UTKICHUQEQBDGC-ACZMJKKPSA-N Glu-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UTKICHUQEQBDGC-ACZMJKKPSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- LZEUDRYSAZAJIO-AUTRQRHGSA-N Glu-Val-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZEUDRYSAZAJIO-AUTRQRHGSA-N 0.000 description 1
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RGPWUJOMKFYFSR-QWRGUYRKSA-N His-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RGPWUJOMKFYFSR-QWRGUYRKSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- UFRXVQGGPNSJRY-CYDGBPFRSA-N Ile-Met-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N UFRXVQGGPNSJRY-CYDGBPFRSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- UCOCBWDBHCUPQP-DCAQKATOSA-N Leu-Arg-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O UCOCBWDBHCUPQP-DCAQKATOSA-N 0.000 description 1
- IGUOAYLTQJLPPD-DCAQKATOSA-N Leu-Asn-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IGUOAYLTQJLPPD-DCAQKATOSA-N 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- SVBJIZVVYJYGLA-DCAQKATOSA-N Leu-Ser-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O SVBJIZVVYJYGLA-DCAQKATOSA-N 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010054877 Mucosal discolouration Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- KOUUGTKGEQZRHV-KKUMJFAQSA-N Phe-Gln-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O KOUUGTKGEQZRHV-KKUMJFAQSA-N 0.000 description 1
- FINLZXKJWTYYLC-ACRUOGEOSA-N Phe-His-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FINLZXKJWTYYLC-ACRUOGEOSA-N 0.000 description 1
- CZQZSMJXFGGBHM-KKUMJFAQSA-N Phe-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O CZQZSMJXFGGBHM-KKUMJFAQSA-N 0.000 description 1
- XZONQWUEBAFQPO-HJGDQZAQSA-N Pro-Gln-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZONQWUEBAFQPO-HJGDQZAQSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- CLKKNZQUQMZDGD-SRVKXCTJSA-N Ser-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 CLKKNZQUQMZDGD-SRVKXCTJSA-N 0.000 description 1
- RIAKPZVSNBBNRE-BJDJZHNGSA-N Ser-Ile-Leu Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O RIAKPZVSNBBNRE-BJDJZHNGSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- QGXCWPNQVCYJEL-NUMRIWBASA-N Thr-Asn-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QGXCWPNQVCYJEL-NUMRIWBASA-N 0.000 description 1
- DCCGCVLVVSAJFK-NUMRIWBASA-N Thr-Asp-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O DCCGCVLVVSAJFK-NUMRIWBASA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 1
- SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 1
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 1
- XBRMBDFYOFARST-AVGNSLFASA-N Val-His-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N XBRMBDFYOFARST-AVGNSLFASA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000012307 pale mucous membrane Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
A therapeutic agent for feline immunodeficiency virus (FIV)infections, comprising a feline interferon preparation containing a feline interferon as a principal agent (including the treatment of the anemia and chronic stomatitis caused by infection with a FIV) and a therapeutic method for FIV infections by administering a feline interferon preparation containing a feline interferon as a principal agent to a cat continuously every day are disclosed. Furthermore, a therapeutic method and agent for feline atopic dermatitis are disclosed. As the feline interferon, an .omega.-feline interferon, particularly a genetically recombinant type .omega.-feline interferon can be preferably used. The .omega.-feline interferon can be an interferon combined with a sugar chain having the amino acid-sequence shown in sequence number: 1.
Description
THERAPEUTIC AGENT CONTAINING w-FELINE INTERFERON FOR TREATING
FELINE AIDS VIRUS INFECTIONS AND FELINE ATOPIC DERMATITIS
Technical field The present invention relates to a therapeutic agent and method for feline AIDS virus(FIV)infections and feline atopic dermatitis. A FIV belongs to Lentivirinae of Retroviridae, and cats living freely outdoors are often infected with it.
FIV infections are said to undergo three stages; initial acute stage of virus*infection, latent stage, and last chronic disease stage of immunodeficiency.
In the initial stage of infection, fever and impotence can be observed, and lymphopenia and neutropenia occur. The skin and digestive tracts can happen to suffer microbism, but these are secondary infections by neutropenia. Vomition and anemia can also be observed. After the symptoms in the acute stage vanish, the latent stage continues for several months to several years.
In the last stage, chronic diseases such as chronic stomatitis, chronic respiratory organ diseases, anemia, intractable secondary microbism and enteritis occur, and the carriers become gradually weak in several years, to finally die. Furthermore, opportunistic infections such as Haemobartonella diseases and Cryptococcus diseases can be seen.
Prior Arts Therapy of FIV infections is still untapped, and no therapeutic method has been developed for eliminating FIV, i.e., a retrovirus from the feline body after infection.
Since therapeutic agents for human AIDS are developed, it can be considered to use them as anti-FIV drugs for cats in future, but the application of a reverse transcriptase inhibitor such as AZT (azidothymidine) seems to be difficult for the time being, considering its side effects and the desired effect to be achieved.
At present, symptomatic therapeutic methods for microbism such as the administration of antibiotics, infusion and blood infusion and administration of steroid hormone preparations are used.
Anemia as one of FIV infections can be seen in the early stage and last stage of FIV virus infection, and at the onset, vitality vanishes and appetite diminishes or is lost.
Furthermore, erythroid values such as erythrocytes, hemoglobin and hematocrit decrease. Symptomatic therapeutic methods such as the administration of erythropoietin and the infusion of vitamins, amino acids, etc., and as the case may be, blood infusion are used. However, most carriers die though these methods have some macrobiotic effect.
Chronic stomatitis as one of FIV infections is an intractable disease, and the inflammation of the gum near the roots of molar teeth causes heavy swelling, not allowing eating. Weakened cats in this stage come to hospital.
Steroid hormone preparations such as Depo-Metrol*are administered to temporarily improve the inflammation as a symptomatic therapeutic method. However, the disease recurs in 2 to 3 weeks, and the administration of steroid hormone preparations is practiced again. The recurrence period becomes gradually shorter, and partly because of side effects by steroid hormone preparations, the cats die finally.
As a feline rnterferon, a genetically recombinant type w-interferon preparation is already approved as a therapeutic agent for calicivirus infections, and is marketed under the trade mark "INTERCAT" since February, 1994. The inventors studied a therapeutic method for FIV infections using this genetically recombinant type w-interferon, and as a result, completed the present invention.
Presently known interferons include alpha (a) interferons, beta (Q) interferon, gamma(T) interferon, omega (co) interferon and tau (t) interferon. As human interferons, three types of a,A and r are practically applied, and as a feline interferon, an cw-interferon only is practically applied. "INTERCAT" is a genetically recombinant type co-feline interferon preparation, and it is an injection preparation obtained by infecting Bombyx mori with a baculovirus recombined with the gene of an cv-feline *Trade-mark interferon, producing the interferon in the body, extracting and purifying it, adding gelatin and D-sorbitol as a stabilizer and recipient, and freeze-drying the mixture. The genetically recombinant type w-feline interferon is a glycoprotein with a molecular weight of about 25000, and its protein portion has the amino acid sequence as shown in sequence 1 of the sequence table.
The co-feline interferon can also be produced by other methods than the Bombyx mori method. For example, it can be produced by transient expression methods using animal cells such as simian COS cells and gene recombination techniques using Chinese hamster's CHO cells, Escherichia coli, yeast, trans-genic animals, etc.
As for the usage and dose of "INTERCAT" approved as a therapeutic agent for calicivirus infections, it is specified_ to administer 2.5 ~- 5 MU/kg of feline interferon intravenously three times every other day. In this case, MU (mega unit) is a method for expressing a titer with the antiviral activity of an interferon as an indicator, and expresses one million units. The inventors attempted to treat FIV infections, particularly anemia and chronic stomatitis according to the same usage and dose of every-other-day administration as approved for treating calicivirus infections, but expected effects could not be obtained. So, the inventors studied further by changing the usage and dose.
FELINE AIDS VIRUS INFECTIONS AND FELINE ATOPIC DERMATITIS
Technical field The present invention relates to a therapeutic agent and method for feline AIDS virus(FIV)infections and feline atopic dermatitis. A FIV belongs to Lentivirinae of Retroviridae, and cats living freely outdoors are often infected with it.
FIV infections are said to undergo three stages; initial acute stage of virus*infection, latent stage, and last chronic disease stage of immunodeficiency.
In the initial stage of infection, fever and impotence can be observed, and lymphopenia and neutropenia occur. The skin and digestive tracts can happen to suffer microbism, but these are secondary infections by neutropenia. Vomition and anemia can also be observed. After the symptoms in the acute stage vanish, the latent stage continues for several months to several years.
In the last stage, chronic diseases such as chronic stomatitis, chronic respiratory organ diseases, anemia, intractable secondary microbism and enteritis occur, and the carriers become gradually weak in several years, to finally die. Furthermore, opportunistic infections such as Haemobartonella diseases and Cryptococcus diseases can be seen.
Prior Arts Therapy of FIV infections is still untapped, and no therapeutic method has been developed for eliminating FIV, i.e., a retrovirus from the feline body after infection.
Since therapeutic agents for human AIDS are developed, it can be considered to use them as anti-FIV drugs for cats in future, but the application of a reverse transcriptase inhibitor such as AZT (azidothymidine) seems to be difficult for the time being, considering its side effects and the desired effect to be achieved.
At present, symptomatic therapeutic methods for microbism such as the administration of antibiotics, infusion and blood infusion and administration of steroid hormone preparations are used.
Anemia as one of FIV infections can be seen in the early stage and last stage of FIV virus infection, and at the onset, vitality vanishes and appetite diminishes or is lost.
Furthermore, erythroid values such as erythrocytes, hemoglobin and hematocrit decrease. Symptomatic therapeutic methods such as the administration of erythropoietin and the infusion of vitamins, amino acids, etc., and as the case may be, blood infusion are used. However, most carriers die though these methods have some macrobiotic effect.
Chronic stomatitis as one of FIV infections is an intractable disease, and the inflammation of the gum near the roots of molar teeth causes heavy swelling, not allowing eating. Weakened cats in this stage come to hospital.
Steroid hormone preparations such as Depo-Metrol*are administered to temporarily improve the inflammation as a symptomatic therapeutic method. However, the disease recurs in 2 to 3 weeks, and the administration of steroid hormone preparations is practiced again. The recurrence period becomes gradually shorter, and partly because of side effects by steroid hormone preparations, the cats die finally.
As a feline rnterferon, a genetically recombinant type w-interferon preparation is already approved as a therapeutic agent for calicivirus infections, and is marketed under the trade mark "INTERCAT" since February, 1994. The inventors studied a therapeutic method for FIV infections using this genetically recombinant type w-interferon, and as a result, completed the present invention.
Presently known interferons include alpha (a) interferons, beta (Q) interferon, gamma(T) interferon, omega (co) interferon and tau (t) interferon. As human interferons, three types of a,A and r are practically applied, and as a feline interferon, an cw-interferon only is practically applied. "INTERCAT" is a genetically recombinant type co-feline interferon preparation, and it is an injection preparation obtained by infecting Bombyx mori with a baculovirus recombined with the gene of an cv-feline *Trade-mark interferon, producing the interferon in the body, extracting and purifying it, adding gelatin and D-sorbitol as a stabilizer and recipient, and freeze-drying the mixture. The genetically recombinant type w-feline interferon is a glycoprotein with a molecular weight of about 25000, and its protein portion has the amino acid sequence as shown in sequence 1 of the sequence table.
The co-feline interferon can also be produced by other methods than the Bombyx mori method. For example, it can be produced by transient expression methods using animal cells such as simian COS cells and gene recombination techniques using Chinese hamster's CHO cells, Escherichia coli, yeast, trans-genic animals, etc.
As for the usage and dose of "INTERCAT" approved as a therapeutic agent for calicivirus infections, it is specified_ to administer 2.5 ~- 5 MU/kg of feline interferon intravenously three times every other day. In this case, MU (mega unit) is a method for expressing a titer with the antiviral activity of an interferon as an indicator, and expresses one million units. The inventors attempted to treat FIV infections, particularly anemia and chronic stomatitis according to the same usage and dose of every-other-day administration as approved for treating calicivirus infections, but expected effects could not be obtained. So, the inventors studied further by changing the usage and dose.
A task of the present invention is to provide a new excellent therapeutic agent and method for FIV infections.
On the other hand, for feline atopic dermatitis, there is no satisfactory therapeutic method even for human atopic dermatitis, and symptomatic therapeutic methods using steroid hormone preparations are frequently adopted. Steroid hormone preparations have side effects, and the symptomatic therapeutic methods are insufficient in therapeutic effect.
Feline atopic dermatitis is an intractable disease. Generally observed feline allergic dermatitis is mostly atopic dermatitis including miiiary eczema relating to parasites such as fleas and eosinophilic granuloma syndrome. Hitherto, drugs such as prednisolone and amcinolone are said to be effective, and they tend to be used more frequently. However, these drugs have a problem of side effects.
It was reported in an American medical magazine in 1990 (M. Boouniewwicz et al., American J. Medicine, 8.8, 365-370 (1990)) that a human r(gamma) interferon is effective for human atopic dermatitis.
However, this method is not sufficient in the effect of treating feline atopic dermatitis since human interferons are different in action from feline interferons.
Another task of the present invention is to provide a new excellent therapeutic agent and method for feline atopic dermatitis.
Disclosure of the Invention As a result of studies conducted by the present inventors, it has been found that anemia and chronic stomatitis caused by infection with a FIV, confirmed to be positive in anti-FIV antibody by virus tests of feline blood, can be treated by using a therapeutic agent containing an w-feline interferon.
Furthermore, it has been found that a therapeutic agent containing an w-feline interferon is a new excellent therapeutic agent for feline atopic stomatitis.
Thus, aspects and embodiments of the present invention are as follows:
[1] A therapeutic agent for FIV infections, comprising a feline interferon preparation containing a feline interferon as a principal agent.
[2] A therapeutic agent for FIV infections, according to [1], wherein the feline interferon is an w feline interferon.
[3] A therapeutic agent for feline AIDS virus infections, according to [2], wherein the w-feline interferon is a genetically recombinant type interferon.
[4] A therapeutic agent for FIV infections, according to ,[3], wherein the w-feline interferon is an interferon combined with a sugar chain having the amino acid sequence shown in sequence number: 1.
On the other hand, for feline atopic dermatitis, there is no satisfactory therapeutic method even for human atopic dermatitis, and symptomatic therapeutic methods using steroid hormone preparations are frequently adopted. Steroid hormone preparations have side effects, and the symptomatic therapeutic methods are insufficient in therapeutic effect.
Feline atopic dermatitis is an intractable disease. Generally observed feline allergic dermatitis is mostly atopic dermatitis including miiiary eczema relating to parasites such as fleas and eosinophilic granuloma syndrome. Hitherto, drugs such as prednisolone and amcinolone are said to be effective, and they tend to be used more frequently. However, these drugs have a problem of side effects.
It was reported in an American medical magazine in 1990 (M. Boouniewwicz et al., American J. Medicine, 8.8, 365-370 (1990)) that a human r(gamma) interferon is effective for human atopic dermatitis.
However, this method is not sufficient in the effect of treating feline atopic dermatitis since human interferons are different in action from feline interferons.
Another task of the present invention is to provide a new excellent therapeutic agent and method for feline atopic dermatitis.
Disclosure of the Invention As a result of studies conducted by the present inventors, it has been found that anemia and chronic stomatitis caused by infection with a FIV, confirmed to be positive in anti-FIV antibody by virus tests of feline blood, can be treated by using a therapeutic agent containing an w-feline interferon.
Furthermore, it has been found that a therapeutic agent containing an w-feline interferon is a new excellent therapeutic agent for feline atopic stomatitis.
Thus, aspects and embodiments of the present invention are as follows:
[1] A therapeutic agent for FIV infections, comprising a feline interferon preparation containing a feline interferon as a principal agent.
[2] A therapeutic agent for FIV infections, according to [1], wherein the feline interferon is an w feline interferon.
[3] A therapeutic agent for feline AIDS virus infections, according to [2], wherein the w-feline interferon is a genetically recombinant type interferon.
[4] A therapeutic agent for FIV infections, according to ,[3], wherein the w-feline interferon is an interferon combined with a sugar chain having the amino acid sequence shown in sequence number: 1.
[5] A therapeutic agent for FIV infections, according to any one of [1] through [4], which is used for treating the anemia caused by infection with a FIV.
[6] A therapeutic agent for FIV infections, according to any one of [1] through-[4], which is used for treating the chronic stomatitis caused by infection with a FIV.
[7] A therapeutic method for FIV infections, comprising the step of administering a feline interferon preparation containing a feline interferon as a principal'agent to a cat continuously every day.
[8] A therapeutic method'for FIV infections, according to [7], wherein the feline interferon is an co feline interferon.
[9] A therapeutic method for FIV infections, according to, [8], wherein the co-feline interferon is a genetically recombinant type interferon.
[10] A therapeutic method for FIV infections, according to [9], wherein the cw-feline interferon is an interferon combined with a sugar chain having the amino acid sequence shown in sequence number: 1.
[11] A therapeutic method for FIV infections, according to any one of [7] through [10], which is usEd for treating the anemia caused by infection with a FIV.
[121 A therapeutic method for FIV infections, according to any one of [7] through [10], which is used for treating the chronic stomatitis caused by infection with a FIV.
[13] A therapeutic method for FIV infections, according to any one of [7] through [12], wherein the co-feline interferon is administered by a dose of 0.5 MU/kg - 2.5 MU/kg per cat body weight once or more per day for 5 or more consecutive days.
[14] A therapeutic agent for feline atopic dermatitis, comprising a feline interferon.
[15] A therapeutic agent for feline atopic dermatitis, according to [141, wherein the feline interferon is an co-feline interferon.
[16] A therapeutic agent for feline atopic dermatitis, according to [15], wherein the co-feline interferon is a genetically recombinant type interferon.
[17] A therapeutic agent for feline atopic dermatitis, according to [15] or [16], wherein the co-feline interferon is an interferon combined with a sugar chain having the amino acid sequence shown by sequence number: 1.
[18] A therapeutic method for feline atopic dermatitis, wherein the therapeutic agent for atopic dermatitis stated in any one of [14] through [17] is injected into a cat.
[19] A therapeutic method for feline atopic dermatitis, according to [18], wherein the injection is subcutaneous injection.
[20] A therapeutic method for feline atopic dermatitis, according to [18] or [19], wherein the dose is 0.1 - 5 MU/kg.
The Best Embodiments of the Invention The therapeutic agent is a pharmaceutical preparation containing the feline interferon as well as a pharmaceutically acceptable diluent. The pharmaceutical preparation is preferably in a form adapted for injection.
As well known in the art, such a pharmaceutical preparation may be put in a container for practical storage, transportation, use or the like and the container may be put in a commercial package. Such a commercial package normally carries a written matter describing an indication of the pharmaceutical preparation among others.
An aspect of the present invention provides a use of the interferon for treating FIV infections, such as anemia and chronic stomatitis.
It is preferable that the feline interferon used in the present invention is an w-feline interferon which can be as produced naturally or can be synthetically synthesized or by any gene recombination technique.
For example, an w-feline interferon produced by a gene recombination technique and marketed under the trade mark "INTERCAT" (produced by Toray Industries, Inc.) can be used.
The "INTERCAT" has been approved and practically applied as a therapeutic agent for feline calicivirus infections, and mainly contains an interferon combined with a sugar chain having the sequence of 170 amino acids shown in SEQ ID NO: 1, and it is obtained by infecting larvae of Bombyx mori with a recombinant baculovirus, i.e., and insect virus recombined with the gene of an w-feline interferon, and extracting, separating and refining the interferon produced in the bodies of Bombyx mori.
However, the w-feline interferon of the present invention is not necessarily limited to the genetically recombinant type feline interferon.
9a The a-feline interferons produced by gene manipula.tion using Escherichia coli, Bacillus subtilis and animal cells such as CHO and also the co-interferon produced from feline cells can also be used. However, in the present situation, the co feline interferon produced from Bombyx mori is available at low cost.
At first, the therapeutic method for FIV infections is described. The therapeutic method is to inject a therapeutic agent containing an w feline interferon into a cat once or more per day for 5 or more consecutive days. The dose of the feline interferon is 0.5 MU/kg - 2.5 MU/kg per cat body weight.
It is practical to administer the therapeutic agent once a day. It can be administered once or more per day, but it is preferable to administer at least once a'day. It is desirable to administer every day, instea,d of every other day, and it is more desirable to administer continuously for 5 days or more.
After administering continuously for 5 days or more, the administration can be once suspended, and subsequently continuous administration can be effected again for 5 or more consecutive days.
The dose can also be smaller than 0.5 MU/kg, but if the dose is smaller than 0.5 MU/kg, the therapeutic effect is also weaker. On the contrary, even if the dose is larger than 2.5 MU/kg, the therapeutic cost simply increases, without giving any correspondingly higher effect in most cases.
The injection route can be subcutaneous or intravenous.
Intramuscular injection can also be used. However, subcutaneous injection can be practically and simply effected. When the therapeutic method of the present invention was used for treating the anemia as one of feline AIDS virus infections, recovery from impotence and increase of appetite could be achieved, and erythroid values such as erythrocytes, hemoglobin and hematocrit increased.
When used to treat chronic stomatitis, the stomatitis accompanying the ulcers and granulomata of fauces improved and appetite and vitality were restored.
Feline atopic dermatitis is described below. The therapeutic agent for feline atopic dermatitis of the present invention is a preparation containing an w- feline i nterferon as a principal agent, and when it is used, a solution obtained by dissolving it into physiologic salt solution or infusion solution or any other solution is injected. The injection route can be subcutaneous, intravenous or intramuscular.
Subcutaneous injection is preferably simple and practical.
The number of administration times is not especially limited, but it is practical to administer once a day every day or 1 to 3 times per week. The dose is not limited either, but is usually 0.1 to 5 MU/kg. A preferable range is 1 to 2.5 MU/kg.
The administration effect can be clearly observed from about 1t the 2nd week in most cases.
The co-feline interferons usually do not cause remarkable fever after administration unlike human beings, and even if fever occurs, the body temperature rise as slight as about 1 C
only occurs for a while. Serious side effects such as vomition and diarrhea are not caused.
Examples The present invention is described-below in reference to examples, but is not limited thereto or thereby. The blood cell count is in number per microliter (/ ul).
[Example 1]
A genetically recombinant type co-feline interferon preparation (trade mark: INTERCAT) was administered to a Japanese cat (female) of 3 to 4 years old who had been suffering the anemia caused by FIV infection . On the day of the first medical examination, the body weight was 3.7 kg, and she had lost appetite from the previous day, remained impotent and showed pale mucous membranes.
Tetracycline was subcutaneously injected by 1.85 mi, and a vitamin preparation was subcutaneously dripped by 500 ml. On the following day, the body weight became 4.0 kg. In a virus check, she was positive in anti-FIV antibody and negative in FeLV antigen. Blood examination values were WBC 12600, erythrocytes 144,000, hemoglobin 3.7 g/dl, hematocrit 12.3%, mean cell volume (MCV) 85 fl, mean cell hemoglobin concentration (MCHC) 30.1 g/dI and thrombocytes 163,000.-INTERCAT wa.s dissolved into physiological salt solution, and the INTERCAT solution was subcutaneously injected by 10 MU/day for 3 days. The dose per body weight was 2.5 MU/kg.
An infusion solution (vitamin preparation) was subcutaneously dripped by 500 mi/day, and an antibiotic (tetracycline) was subcutaneously injected by 1.85 ml.
From the.4th day, Inter-Cat was decreased to 4 MU/day, and subcutaneously injected for 4 days. The dose per body weight was 0.75 MU/kg.
On the 5th day, appetite was restored a little.
On the 8th day, blood examination values were WBC 10400, erythrocytes 358, hemoglobin 4.9 g/dI, hematocrit 28.5%, mean cell volume (MCV) 65 fI, mean cell hemoglobin concentration (MCHC) 30.2 g/dI and thrombocytes 178,000. The body weight was 3.4 kg.
Still after the 85th day, vitality and appetite remained normal. The blood examination values were WBC 11400, erythrocytes 971, hemoglobin 11.8 g/dl, hematocrit 40.3%, mean cell volume (MCV) 42 fI, mean cell hemoglobin concentration (MCHC) 29.3 g/dI and thrombocytes 198,000. The body weight was 3.9 kg.
[Example 2]
A genetically recombinant type co feline interferon preparation (trade mark: INTERCAT) was administered to a Japanese cat (male) of 6 to 7 years old who had been suffering the anemia caused by infection with a feline AIDS virus. On the day of the first medical examination, the body weight was 7.55 kg. Appetite had declined from the previous day, and he was impotent.
In a virus test, he was positive in anti-FIV antibody and negative in FeLV antigen. An anti-inflammatory drug, loxoprofen sodium was administered by 1/2 tablet twice a day.
The blood examination values were WBC 3500, erythrocytes 3, 670, 000, hemog l ob i n 5.3 g/d I, hematoc r i t 18.4%, mean c.e l l volume (MCV) 50 fl, mean cell hemoglobin concentration (MCHC) 31.5 g/dI and thrombocytes 105,000.
INTERCAT was dissolved into physiological salt solution, and the INTERCAT solution was subcutaneously injected by 10 MU/day for 3 days. On the 4th day, the dose was decreased to_ 2.5 MU/day, and the INTERCAT solution was subcutaneously injected for further 3 days. From the 7th day, the dose was increased to 10 MU/day, and the INTERCAT solution was subcutaneously injected for 3 days.
On the 9th day, the blood test values were WBC 10600, erythrocytes 4, 020, 000, hemoglobin 6.4 g/dI, hematocrit 21.0%, mean ce I I vo I ume (MCV) 52 f I, mean ce I I hemog I ob i n concentration (MCHC) 30.5 g/dl and thrombocytes 351,000.
Appetite was restored a little. The body weight was 7.3 kg.
On the 18th day, he came to hospital again due to anorexia. The body weight was 7.05 kg. The blood exami~nation' values were WBC 6900, erythrocytes 10,430,000, hemoglobin 16.0 g/dI, hematocrit 51.7%, mean cell volume (MCV) 50 fI, mean cell hemoglobin concentration (MCHC) 30.9 g/dI and thrombocytes 324,000.
INTERCAT was subcutaneously injected by 10 MU/day for 7 *
days. An antibiotic (Baytril) was administered by 1/2 tablet twice a day. Infusion was effected on the 18th day only.
Still after one month, vitality and appetite remained recovered.
[Examp l e 3]
A genetically recombinant type co feline interferon preparation (trade mark: INTERCAT) was administered to a 10-year-old Japanese cat (male) who had been suffering the chronic stomatitis caused by FIV infection. On the day of the first medical examination, the body weight was 4.6 kg, and saliva and the ulcers and granulomat of fauces on both sides were observed. In a virus test, he was positive in anti-FIV
antibody and negative in FeLV antigen.
INTERCAT was dissolved in physiological salt solution, and the INTERCAT solution was subcutaneously injected by 10 MU/day for 3 days. The dose per body weight was 2.17 MU/kg. After the 4th day, the dose was decreased to 4 MU/day, and the Inter-Cat solution was subcutaneously injected for further 4 days. Only on the 2nd day, an infusion solution (vitamin *Trade-mark preparation) was subcutaneously dripped by 500 ml. An antibiotic (Baytril) was administered every day.
On the 3rd day, appetite was restored a little. Saliva was also improved a little. As for the stomatitis, the granuloma on the left side became slightly less reddish.
On the 4th day, as for the stomatitis, the granuloma on the left side was reduced in size and reddishness.
On the 5th day, as for the stomatitis, the granuloma on the right side vanished, and the granuloma on the left side was further reduced in reddishness.
On the 7th day, appetite was restored, and as for the stomatitis, ulcers and granulomat vanished. On the 10th day, the body weight was 4.95 kg.
Still after six months, the stomatitis was not worsened.
[Examp l e 41 A genetically recombinant type co-feline interferon preparation (trade mark: INTERCAT) was administered to an 8-year-old Japanese cat (male) who had been suffering the chronic stomatitis caused by infection with a feline AIDS
virus. On the day of the first medical examination, the body weight was 3.4 kg, and saliva and ulcers and granulomat of fauces on both sides were observed. In a virus test, he was positive in anti-FIV antibody and negative in FeLV antigen.
INTERCAT was dissolved into physiological salt solution, and the Inter-Cat solution was subcutaneously injected by 8.5 MU/day for 7 days. The dose per body weight was 2.5 MU/kg.
After the 8th day, the dose was decreased to 4 MU/day, and the INTERCAT solution was subcutaneously injected for further 4 days. On the 2nd day only, an infusion solution (vitamin preparation) was subcutaneously dripped by 300 ml.
~
Antibiotics (Dalacin; clindamycin) were administered every day.
On the 7th day, appetite was restored. The body weight was 3.75 kg. Saliva improved, and the stomatitis also improved.
After two months, the stomatitis was not especially worsened, but Inter-Cat was subcutaneously injected by 2.5 MU/kg for 7 days.
After further six months, the stomatitis was not worsened.
[Examp l e 5]
A 4-year-old unsexed female house cat (short hair, Japanese cat) (white, body weight 2.62 kg) came to hospital for the main reason that red eczema occurred in the abdominal part since several days before, and was diagnosed to suffer atopic dermatitis. A preparation containing a cw feline interferon (recombinant type) as a principal agent, i.e., "INTERCAT" was dissolved into physiological solution, and the INTERCAT solution was subcutaneously injected by 5 MU/head (1.9 MU/kg). The administration of "INTERCAT" was continued at intervals of twice a week, and after 8 weeks, the eczema *Trade-mark iT
perfectly vanished.
[Examp l e 6]
A 3-year-old female house cat (Cornish Rex) (white, body weight 2.76 kg) had eosinophilic plaques formed with the hypertrophy of the dorsolumber skin since several months before, and was cured temporarily by periodical administration of a steroid hormone preparation. However, after a while, many plaques occurred on the face and the back. On the auricles, portions considered to show the generation of a fungus existed. The disease was diagnoised as atopic dermatitis. A preparation containing a co-feline i nterferon (recombinant type) as a principal agent, i.e., "INTERCAT" was dissolved into physiological salt solution, and the INTERCAT
solution was subcutaneously injected by 5 MU/head (1.81 MU/kg). An antihistaminic agent used since before was also used together. The administration of "INTERCAT" was continued at intervals of once a week. From the 2nd week, the reddishness of the eczema began to vanish, and after 3 months, only a trace remained to show almost perfect healing.
[Examp l e 7]
A 6-year-old unsexed female house cat (short hair, Japanese cat) (blackish tiger color, body weight 4.55 kg) had had miliary eczema on the back due to flea allergy since two years before, and the administration of a steroid hormone preparation and thorough flea extermination could bring about ~8 a lesion. However, since about one year before, many eosinophilic plaques were formed in the abdominal part, and through the administration of the steroid hormone preparation showed reaction, the effect gradually diminished. The disease was diagnosed as atopic dermatitis. A preparation containing an w feline interferon (recombinant type) as a principal agent, i.e., "INTERCAT" was dissolved into physiological salt solution, and the INTERCAT solution was subcutaneously injected by 5 MU/head (1.1 MU/kg). The administration of "INTERCAT" continued at intervals of once a week. After 2 weeks, reddishness almost vanished, and still after 2 months, the disease did not recur.
Industrial Applicability The present invention is an effective therapeutic agent containing an w-feline interferon, for treating the anemia and chronic stomatitis caused by FIV infection with a feline AIDS
virus, confirmed by a virus test of feline blood because of being positive in anti-FIV antibody, and also is an effective therapeutic method using said therapeutic agent. Furthermore, the therapeutic agent containing an w-feline interferon is a new excellent therapeutic agent and method for feline atopic dermatitis. The present invention is highly industrially useful.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: TORAY INDUSTRIES, INC.
(ii) TITLE OF INVENTION: THERAPEUTIC AGENT AND METHOD FOR FELINE AIDS
VIRUS INFECTIONS AND FELINE ATOPIC DERMATITIS
(iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: SMART & BIGGAR
(B) STREET: P.O. BOX 2999, STATION D
(C) CITY: OTTAWA
(D) STATE: ONT
(E) COUNTRY: CANADA
(F) ZIP: K1P 5Y6 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (text) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: CA 2,241,941 (B) FILING DATE: 30-OCT-1997 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 8/290601 (B) FILING DATE: 31-OCT-1996 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: SMART & BIGGAR
(B) REGISTRATION NUMBER:
(C) REFERENCE/DOCKET NUMBER: 76199-95 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (613)-232-2486 (B) TELEFAX: (613)-232-8440 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 170 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Cys Asp Leu Pro Gln Thr His Gly Leu Leu Asn Arg Arg Ala Leu Thr Leu Leu Gly Gln Met Arg Arg Leu Pro Ala Ser Ser Cys Gln Lys Asp Arg Asn Asp Phe Ala Phe Pro Gln Asp Val Phe Gly Gly Asp Gin Ser His Lys Ala Gln Ala Leu Ser Val Val His Val Thr Asp Gln Lys Ile 20 Phe His Phe Phe Cys Thr Glu Ala Ser Ser Ser Ala Ala Trp Asn Thr Thr Leu Leu Glu Glu Phe Cys Thr Gly Leu Asp Arg Gln Leu Thr Arg Leu Glu Ala Cys Val Leu Gln Glu Val Glu Glu Gly Glu Ala Pro Leu Thr Asn Glu Asp Ile His Pro Glu Asp Ser Ile Leu Arg Asn Tyr Phe Gln Arg Leu Ser Leu Tyr Leu Glu Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala Glu Ile Met Arg Ser Leu Tyr Tyr Ser Ser Thr Ala Leu Gln Lys Arg Leu Arg Ser Glu - 20a -
[121 A therapeutic method for FIV infections, according to any one of [7] through [10], which is used for treating the chronic stomatitis caused by infection with a FIV.
[13] A therapeutic method for FIV infections, according to any one of [7] through [12], wherein the co-feline interferon is administered by a dose of 0.5 MU/kg - 2.5 MU/kg per cat body weight once or more per day for 5 or more consecutive days.
[14] A therapeutic agent for feline atopic dermatitis, comprising a feline interferon.
[15] A therapeutic agent for feline atopic dermatitis, according to [141, wherein the feline interferon is an co-feline interferon.
[16] A therapeutic agent for feline atopic dermatitis, according to [15], wherein the co-feline interferon is a genetically recombinant type interferon.
[17] A therapeutic agent for feline atopic dermatitis, according to [15] or [16], wherein the co-feline interferon is an interferon combined with a sugar chain having the amino acid sequence shown by sequence number: 1.
[18] A therapeutic method for feline atopic dermatitis, wherein the therapeutic agent for atopic dermatitis stated in any one of [14] through [17] is injected into a cat.
[19] A therapeutic method for feline atopic dermatitis, according to [18], wherein the injection is subcutaneous injection.
[20] A therapeutic method for feline atopic dermatitis, according to [18] or [19], wherein the dose is 0.1 - 5 MU/kg.
The Best Embodiments of the Invention The therapeutic agent is a pharmaceutical preparation containing the feline interferon as well as a pharmaceutically acceptable diluent. The pharmaceutical preparation is preferably in a form adapted for injection.
As well known in the art, such a pharmaceutical preparation may be put in a container for practical storage, transportation, use or the like and the container may be put in a commercial package. Such a commercial package normally carries a written matter describing an indication of the pharmaceutical preparation among others.
An aspect of the present invention provides a use of the interferon for treating FIV infections, such as anemia and chronic stomatitis.
It is preferable that the feline interferon used in the present invention is an w-feline interferon which can be as produced naturally or can be synthetically synthesized or by any gene recombination technique.
For example, an w-feline interferon produced by a gene recombination technique and marketed under the trade mark "INTERCAT" (produced by Toray Industries, Inc.) can be used.
The "INTERCAT" has been approved and practically applied as a therapeutic agent for feline calicivirus infections, and mainly contains an interferon combined with a sugar chain having the sequence of 170 amino acids shown in SEQ ID NO: 1, and it is obtained by infecting larvae of Bombyx mori with a recombinant baculovirus, i.e., and insect virus recombined with the gene of an w-feline interferon, and extracting, separating and refining the interferon produced in the bodies of Bombyx mori.
However, the w-feline interferon of the present invention is not necessarily limited to the genetically recombinant type feline interferon.
9a The a-feline interferons produced by gene manipula.tion using Escherichia coli, Bacillus subtilis and animal cells such as CHO and also the co-interferon produced from feline cells can also be used. However, in the present situation, the co feline interferon produced from Bombyx mori is available at low cost.
At first, the therapeutic method for FIV infections is described. The therapeutic method is to inject a therapeutic agent containing an w feline interferon into a cat once or more per day for 5 or more consecutive days. The dose of the feline interferon is 0.5 MU/kg - 2.5 MU/kg per cat body weight.
It is practical to administer the therapeutic agent once a day. It can be administered once or more per day, but it is preferable to administer at least once a'day. It is desirable to administer every day, instea,d of every other day, and it is more desirable to administer continuously for 5 days or more.
After administering continuously for 5 days or more, the administration can be once suspended, and subsequently continuous administration can be effected again for 5 or more consecutive days.
The dose can also be smaller than 0.5 MU/kg, but if the dose is smaller than 0.5 MU/kg, the therapeutic effect is also weaker. On the contrary, even if the dose is larger than 2.5 MU/kg, the therapeutic cost simply increases, without giving any correspondingly higher effect in most cases.
The injection route can be subcutaneous or intravenous.
Intramuscular injection can also be used. However, subcutaneous injection can be practically and simply effected. When the therapeutic method of the present invention was used for treating the anemia as one of feline AIDS virus infections, recovery from impotence and increase of appetite could be achieved, and erythroid values such as erythrocytes, hemoglobin and hematocrit increased.
When used to treat chronic stomatitis, the stomatitis accompanying the ulcers and granulomata of fauces improved and appetite and vitality were restored.
Feline atopic dermatitis is described below. The therapeutic agent for feline atopic dermatitis of the present invention is a preparation containing an w- feline i nterferon as a principal agent, and when it is used, a solution obtained by dissolving it into physiologic salt solution or infusion solution or any other solution is injected. The injection route can be subcutaneous, intravenous or intramuscular.
Subcutaneous injection is preferably simple and practical.
The number of administration times is not especially limited, but it is practical to administer once a day every day or 1 to 3 times per week. The dose is not limited either, but is usually 0.1 to 5 MU/kg. A preferable range is 1 to 2.5 MU/kg.
The administration effect can be clearly observed from about 1t the 2nd week in most cases.
The co-feline interferons usually do not cause remarkable fever after administration unlike human beings, and even if fever occurs, the body temperature rise as slight as about 1 C
only occurs for a while. Serious side effects such as vomition and diarrhea are not caused.
Examples The present invention is described-below in reference to examples, but is not limited thereto or thereby. The blood cell count is in number per microliter (/ ul).
[Example 1]
A genetically recombinant type co-feline interferon preparation (trade mark: INTERCAT) was administered to a Japanese cat (female) of 3 to 4 years old who had been suffering the anemia caused by FIV infection . On the day of the first medical examination, the body weight was 3.7 kg, and she had lost appetite from the previous day, remained impotent and showed pale mucous membranes.
Tetracycline was subcutaneously injected by 1.85 mi, and a vitamin preparation was subcutaneously dripped by 500 ml. On the following day, the body weight became 4.0 kg. In a virus check, she was positive in anti-FIV antibody and negative in FeLV antigen. Blood examination values were WBC 12600, erythrocytes 144,000, hemoglobin 3.7 g/dl, hematocrit 12.3%, mean cell volume (MCV) 85 fl, mean cell hemoglobin concentration (MCHC) 30.1 g/dI and thrombocytes 163,000.-INTERCAT wa.s dissolved into physiological salt solution, and the INTERCAT solution was subcutaneously injected by 10 MU/day for 3 days. The dose per body weight was 2.5 MU/kg.
An infusion solution (vitamin preparation) was subcutaneously dripped by 500 mi/day, and an antibiotic (tetracycline) was subcutaneously injected by 1.85 ml.
From the.4th day, Inter-Cat was decreased to 4 MU/day, and subcutaneously injected for 4 days. The dose per body weight was 0.75 MU/kg.
On the 5th day, appetite was restored a little.
On the 8th day, blood examination values were WBC 10400, erythrocytes 358, hemoglobin 4.9 g/dI, hematocrit 28.5%, mean cell volume (MCV) 65 fI, mean cell hemoglobin concentration (MCHC) 30.2 g/dI and thrombocytes 178,000. The body weight was 3.4 kg.
Still after the 85th day, vitality and appetite remained normal. The blood examination values were WBC 11400, erythrocytes 971, hemoglobin 11.8 g/dl, hematocrit 40.3%, mean cell volume (MCV) 42 fI, mean cell hemoglobin concentration (MCHC) 29.3 g/dI and thrombocytes 198,000. The body weight was 3.9 kg.
[Example 2]
A genetically recombinant type co feline interferon preparation (trade mark: INTERCAT) was administered to a Japanese cat (male) of 6 to 7 years old who had been suffering the anemia caused by infection with a feline AIDS virus. On the day of the first medical examination, the body weight was 7.55 kg. Appetite had declined from the previous day, and he was impotent.
In a virus test, he was positive in anti-FIV antibody and negative in FeLV antigen. An anti-inflammatory drug, loxoprofen sodium was administered by 1/2 tablet twice a day.
The blood examination values were WBC 3500, erythrocytes 3, 670, 000, hemog l ob i n 5.3 g/d I, hematoc r i t 18.4%, mean c.e l l volume (MCV) 50 fl, mean cell hemoglobin concentration (MCHC) 31.5 g/dI and thrombocytes 105,000.
INTERCAT was dissolved into physiological salt solution, and the INTERCAT solution was subcutaneously injected by 10 MU/day for 3 days. On the 4th day, the dose was decreased to_ 2.5 MU/day, and the INTERCAT solution was subcutaneously injected for further 3 days. From the 7th day, the dose was increased to 10 MU/day, and the INTERCAT solution was subcutaneously injected for 3 days.
On the 9th day, the blood test values were WBC 10600, erythrocytes 4, 020, 000, hemoglobin 6.4 g/dI, hematocrit 21.0%, mean ce I I vo I ume (MCV) 52 f I, mean ce I I hemog I ob i n concentration (MCHC) 30.5 g/dl and thrombocytes 351,000.
Appetite was restored a little. The body weight was 7.3 kg.
On the 18th day, he came to hospital again due to anorexia. The body weight was 7.05 kg. The blood exami~nation' values were WBC 6900, erythrocytes 10,430,000, hemoglobin 16.0 g/dI, hematocrit 51.7%, mean cell volume (MCV) 50 fI, mean cell hemoglobin concentration (MCHC) 30.9 g/dI and thrombocytes 324,000.
INTERCAT was subcutaneously injected by 10 MU/day for 7 *
days. An antibiotic (Baytril) was administered by 1/2 tablet twice a day. Infusion was effected on the 18th day only.
Still after one month, vitality and appetite remained recovered.
[Examp l e 3]
A genetically recombinant type co feline interferon preparation (trade mark: INTERCAT) was administered to a 10-year-old Japanese cat (male) who had been suffering the chronic stomatitis caused by FIV infection. On the day of the first medical examination, the body weight was 4.6 kg, and saliva and the ulcers and granulomat of fauces on both sides were observed. In a virus test, he was positive in anti-FIV
antibody and negative in FeLV antigen.
INTERCAT was dissolved in physiological salt solution, and the INTERCAT solution was subcutaneously injected by 10 MU/day for 3 days. The dose per body weight was 2.17 MU/kg. After the 4th day, the dose was decreased to 4 MU/day, and the Inter-Cat solution was subcutaneously injected for further 4 days. Only on the 2nd day, an infusion solution (vitamin *Trade-mark preparation) was subcutaneously dripped by 500 ml. An antibiotic (Baytril) was administered every day.
On the 3rd day, appetite was restored a little. Saliva was also improved a little. As for the stomatitis, the granuloma on the left side became slightly less reddish.
On the 4th day, as for the stomatitis, the granuloma on the left side was reduced in size and reddishness.
On the 5th day, as for the stomatitis, the granuloma on the right side vanished, and the granuloma on the left side was further reduced in reddishness.
On the 7th day, appetite was restored, and as for the stomatitis, ulcers and granulomat vanished. On the 10th day, the body weight was 4.95 kg.
Still after six months, the stomatitis was not worsened.
[Examp l e 41 A genetically recombinant type co-feline interferon preparation (trade mark: INTERCAT) was administered to an 8-year-old Japanese cat (male) who had been suffering the chronic stomatitis caused by infection with a feline AIDS
virus. On the day of the first medical examination, the body weight was 3.4 kg, and saliva and ulcers and granulomat of fauces on both sides were observed. In a virus test, he was positive in anti-FIV antibody and negative in FeLV antigen.
INTERCAT was dissolved into physiological salt solution, and the Inter-Cat solution was subcutaneously injected by 8.5 MU/day for 7 days. The dose per body weight was 2.5 MU/kg.
After the 8th day, the dose was decreased to 4 MU/day, and the INTERCAT solution was subcutaneously injected for further 4 days. On the 2nd day only, an infusion solution (vitamin preparation) was subcutaneously dripped by 300 ml.
~
Antibiotics (Dalacin; clindamycin) were administered every day.
On the 7th day, appetite was restored. The body weight was 3.75 kg. Saliva improved, and the stomatitis also improved.
After two months, the stomatitis was not especially worsened, but Inter-Cat was subcutaneously injected by 2.5 MU/kg for 7 days.
After further six months, the stomatitis was not worsened.
[Examp l e 5]
A 4-year-old unsexed female house cat (short hair, Japanese cat) (white, body weight 2.62 kg) came to hospital for the main reason that red eczema occurred in the abdominal part since several days before, and was diagnosed to suffer atopic dermatitis. A preparation containing a cw feline interferon (recombinant type) as a principal agent, i.e., "INTERCAT" was dissolved into physiological solution, and the INTERCAT solution was subcutaneously injected by 5 MU/head (1.9 MU/kg). The administration of "INTERCAT" was continued at intervals of twice a week, and after 8 weeks, the eczema *Trade-mark iT
perfectly vanished.
[Examp l e 6]
A 3-year-old female house cat (Cornish Rex) (white, body weight 2.76 kg) had eosinophilic plaques formed with the hypertrophy of the dorsolumber skin since several months before, and was cured temporarily by periodical administration of a steroid hormone preparation. However, after a while, many plaques occurred on the face and the back. On the auricles, portions considered to show the generation of a fungus existed. The disease was diagnoised as atopic dermatitis. A preparation containing a co-feline i nterferon (recombinant type) as a principal agent, i.e., "INTERCAT" was dissolved into physiological salt solution, and the INTERCAT
solution was subcutaneously injected by 5 MU/head (1.81 MU/kg). An antihistaminic agent used since before was also used together. The administration of "INTERCAT" was continued at intervals of once a week. From the 2nd week, the reddishness of the eczema began to vanish, and after 3 months, only a trace remained to show almost perfect healing.
[Examp l e 7]
A 6-year-old unsexed female house cat (short hair, Japanese cat) (blackish tiger color, body weight 4.55 kg) had had miliary eczema on the back due to flea allergy since two years before, and the administration of a steroid hormone preparation and thorough flea extermination could bring about ~8 a lesion. However, since about one year before, many eosinophilic plaques were formed in the abdominal part, and through the administration of the steroid hormone preparation showed reaction, the effect gradually diminished. The disease was diagnosed as atopic dermatitis. A preparation containing an w feline interferon (recombinant type) as a principal agent, i.e., "INTERCAT" was dissolved into physiological salt solution, and the INTERCAT solution was subcutaneously injected by 5 MU/head (1.1 MU/kg). The administration of "INTERCAT" continued at intervals of once a week. After 2 weeks, reddishness almost vanished, and still after 2 months, the disease did not recur.
Industrial Applicability The present invention is an effective therapeutic agent containing an w-feline interferon, for treating the anemia and chronic stomatitis caused by FIV infection with a feline AIDS
virus, confirmed by a virus test of feline blood because of being positive in anti-FIV antibody, and also is an effective therapeutic method using said therapeutic agent. Furthermore, the therapeutic agent containing an w-feline interferon is a new excellent therapeutic agent and method for feline atopic dermatitis. The present invention is highly industrially useful.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: TORAY INDUSTRIES, INC.
(ii) TITLE OF INVENTION: THERAPEUTIC AGENT AND METHOD FOR FELINE AIDS
VIRUS INFECTIONS AND FELINE ATOPIC DERMATITIS
(iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: SMART & BIGGAR
(B) STREET: P.O. BOX 2999, STATION D
(C) CITY: OTTAWA
(D) STATE: ONT
(E) COUNTRY: CANADA
(F) ZIP: K1P 5Y6 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: ASCII (text) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: CA 2,241,941 (B) FILING DATE: 30-OCT-1997 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 8/290601 (B) FILING DATE: 31-OCT-1996 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: SMART & BIGGAR
(B) REGISTRATION NUMBER:
(C) REFERENCE/DOCKET NUMBER: 76199-95 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (613)-232-2486 (B) TELEFAX: (613)-232-8440 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 170 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Cys Asp Leu Pro Gln Thr His Gly Leu Leu Asn Arg Arg Ala Leu Thr Leu Leu Gly Gln Met Arg Arg Leu Pro Ala Ser Ser Cys Gln Lys Asp Arg Asn Asp Phe Ala Phe Pro Gln Asp Val Phe Gly Gly Asp Gin Ser His Lys Ala Gln Ala Leu Ser Val Val His Val Thr Asp Gln Lys Ile 20 Phe His Phe Phe Cys Thr Glu Ala Ser Ser Ser Ala Ala Trp Asn Thr Thr Leu Leu Glu Glu Phe Cys Thr Gly Leu Asp Arg Gln Leu Thr Arg Leu Glu Ala Cys Val Leu Gln Glu Val Glu Glu Gly Glu Ala Pro Leu Thr Asn Glu Asp Ile His Pro Glu Asp Ser Ile Leu Arg Asn Tyr Phe Gln Arg Leu Ser Leu Tyr Leu Glu Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Ile Val Arg Ala Glu Ile Met Arg Ser Leu Tyr Tyr Ser Ser Thr Ala Leu Gln Lys Arg Leu Arg Ser Glu - 20a -
Claims (24)
1. A therapeutic agent for treating amnesia or chronic stomatitis, each caused by feline immuno deficiency virus (FIV) infection in a cat, that is a pharmaceutical preparation containing:
.omega.-feline interferon, and a pharmaceutically acceptable diluent.
.omega.-feline interferon, and a pharmaceutically acceptable diluent.
2. The therapeutic agent according to claim 1, wherein the .omega.-feline interferon is a genetically recombinant type interferon.
3. The therapeutic agent according to claim 2, wherein the .omega.-feline interferon has a sugar chain and the amino acid sequence shown in SEQ ID NO: 1.
4. The therapeutic agent according to claim 3, wherein the .omega.-feline interferon is obtained by infecting larvae of Bombyx mori with a gene of the .omega.-feline interferon and extracting, separating and refining the .omega.-feline interferon produced in bodies of Bombyx mori.
5. The therapeutic agent according to any one of claims 1 to 4, wherein the pharmaceutical preparation is in a form adapted for injection.
6. The therapeutic agent according to any one of claims 1 to 5, wherein the .omega.-feline interferon is contained at a dose of 0.5 - 2.5 million units (MU) per kg cat body weight.
7. The therapeutic agent according to any one of claims 1 to 6, for treating anemia caused by FIV infection in a cat.
8. The therapeutic agent according to any one of claims 1 to 6, for treating chronic stomatitis caused by FIV
infection in a cat.
infection in a cat.
9. A commercial package comprising:
a container containing therein the therapeutic agent as defined in any one of claims 1 to 6; and a written matter describing an indication for use of the therapeutic agent in treating anemia or chronic stomatitis caused by feline immunodeficiency virus (FIV) infection in a cat.
a container containing therein the therapeutic agent as defined in any one of claims 1 to 6; and a written matter describing an indication for use of the therapeutic agent in treating anemia or chronic stomatitis caused by feline immunodeficiency virus (FIV) infection in a cat.
10. The commercial package according to claim 9, wherein the indication is for use in treating the anemia.
11. The commercial package according to claim 9, wherein the indication is for use in treating the chronic stomatitis.
12. The commercial package according to any one of claims 9 to 11, wherein the written matter also describes that the therapeutic agent is given to the cat every day.
13. The commercial package according to any one of claims 9 to 12, wherein the written matter further describes that the therapeutic agent is given to the cat once a day.
14. The commercial package according to any one of claims 9 to 13, wherein the written matter also describes that the therapeutic agent is given to the cat for 5 or more consecutive days.
15. The commercial package according to any one of claims 9 to 14, wherein the written matter further describes that the therapeutic agent is given subcutaneously, intravenously or intramuscularly.
16. A use of .omega.-feline interferon for treating anemia or chronic stomatitis, each caused by feline immunodeficiency virus (FIV) in a cat.
17. The use according to claim 16, wherein the .omega.-feline interferon is a genetically recombinant type interferon.
18. The use according to claim 16 or 17, wherein the .omega.-feline interferon has a sugar chain and the amino acid sequence shown in SEQ ID NO: 1.
19. The use according to claim 18, wherein the .omega.-feline interferon is obtained by infecting larvae of Bombyx mori with a gene of the .omega.-feline interferon and extracting, separating and refining the .omega.-feline interferon produced in bodies of Bombyx mori.
20. The use according to any one of claims 16 to 19, wherein the .omega.-feline interferon is in a pharmaceutical preparation form adapted for injection.
21. The use according to any one of claims 16 to 20, wherein the .omega.-feline interferon is contained at a dose of 0.5-2.5 million units (MU) per kg cat body weight.
22. The use according to any one of claims 16 through 21, for treating chronic stomatitis caused by FIV
infection in a cat.
infection in a cat.
23. The use according to any one of claims 16 through 21, for treating anemia caused by FIV infection in a cat.
24. The use according to any one of claims 16 to 23, which occurs every day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2638985A CA2638985C (en) | 1996-10-31 | 1997-10-30 | Therapeutic agent containing .omega.-feline interferon for treating feline atopic dermatitis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8/290601 | 1996-10-31 | ||
| JP29060196A JP3845915B2 (en) | 1996-10-31 | 1996-10-31 | Cat atopic dermatitis therapeutic agent and method of treatment |
| PCT/JP1997/003963 WO1998018484A1 (en) | 1996-10-31 | 1997-10-30 | Therapeutic agent and method for feline aids virus infections and feline atopic dermatitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2638985A Division CA2638985C (en) | 1996-10-31 | 1997-10-30 | Therapeutic agent containing .omega.-feline interferon for treating feline atopic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2241941A1 CA2241941A1 (en) | 1998-05-07 |
| CA2241941C true CA2241941C (en) | 2008-11-18 |
Family
ID=17758124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002241941A Expired - Lifetime CA2241941C (en) | 1996-10-31 | 1997-10-30 | Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis |
| CA2638985A Expired - Lifetime CA2638985C (en) | 1996-10-31 | 1997-10-30 | Therapeutic agent containing .omega.-feline interferon for treating feline atopic dermatitis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2638985A Expired - Lifetime CA2638985C (en) | 1996-10-31 | 1997-10-30 | Therapeutic agent containing .omega.-feline interferon for treating feline atopic dermatitis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6194381B1 (en) |
| EP (2) | EP1743650B1 (en) |
| JP (1) | JP3845915B2 (en) |
| CA (2) | CA2241941C (en) |
| DE (2) | DE69737088T2 (en) |
| ES (2) | ES2323326T3 (en) |
| PT (2) | PT1743650E (en) |
| WO (1) | WO1998018484A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482403B1 (en) | 1998-05-29 | 2002-11-19 | Heska Corporation | Caniney IL-13 immunoregulatory proteins and uses thereof |
| EP1082432A2 (en) | 1998-05-29 | 2001-03-14 | Heska Corporation | Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof |
| USRE40374E1 (en) | 1998-05-29 | 2008-06-10 | Heska Corporation | Canine IL-13 immunoregulatory proteins and uses thereof |
| US20020127200A1 (en) | 1998-05-29 | 2002-09-12 | Shumin Yang | Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof |
| EP2292652A2 (en) * | 2000-11-03 | 2011-03-09 | Pestka Biomedical Laboratories, Inc. | Interferons uses and compositions related thereto |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2071612T3 (en) * | 1987-12-29 | 1995-07-01 | Toray Industries | SYNTHETIC TRANSFORMING PLASMID, FELINE INTERFERON GENE AND METHOD FOR PRODUCING FELINE INTERFERON. |
| JP2982177B2 (en) * | 1989-06-14 | 1999-11-22 | 東レ株式会社 | Expression plasmid, transformed yeast and method for producing feline interferon using the yeast |
| CA2019803C (en) * | 1989-06-29 | 2000-04-25 | Akira Yanai | Feline interferon and process for production thereof |
| JP3640980B2 (en) * | 1993-04-09 | 2005-04-20 | 株式会社林原生物化学研究所 | Cat respiratory remedy and therapeutic method using the same |
| JP3269125B2 (en) * | 1994-01-28 | 2002-03-25 | 東レ株式会社 | Atopic dermatitis drug |
| GB9414752D0 (en) * | 1994-07-21 | 1994-09-07 | Q One Biotech Ltd | Feline gamma-interferon |
| JPH0940580A (en) * | 1995-07-28 | 1997-02-10 | Boehringer Ingelheim Internatl Gmbh | Anti-hiv agent ifn-omega |
-
1996
- 1996-10-31 JP JP29060196A patent/JP3845915B2/en not_active Expired - Lifetime
-
1997
- 1997-10-30 CA CA002241941A patent/CA2241941C/en not_active Expired - Lifetime
- 1997-10-30 DE DE69737088T patent/DE69737088T2/en not_active Expired - Lifetime
- 1997-10-30 PT PT06018590T patent/PT1743650E/en unknown
- 1997-10-30 CA CA2638985A patent/CA2638985C/en not_active Expired - Lifetime
- 1997-10-30 PT PT97909701T patent/PT875251E/en unknown
- 1997-10-30 US US09/101,144 patent/US6194381B1/en not_active Expired - Lifetime
- 1997-10-30 ES ES06018590T patent/ES2323326T3/en not_active Expired - Lifetime
- 1997-10-30 EP EP06018590A patent/EP1743650B1/en not_active Expired - Lifetime
- 1997-10-30 WO PCT/JP1997/003963 patent/WO1998018484A1/en active IP Right Grant
- 1997-10-30 EP EP97909701A patent/EP0875251B1/en not_active Expired - Lifetime
- 1997-10-30 ES ES97909701T patent/ES2275283T3/en not_active Expired - Lifetime
- 1997-10-30 DE DE69739332T patent/DE69739332D1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1743650A2 (en) | 2007-01-17 |
| US6194381B1 (en) | 2001-02-27 |
| EP0875251A4 (en) | 2004-04-21 |
| ES2275283T3 (en) | 2007-06-01 |
| CA2241941A1 (en) | 1998-05-07 |
| WO1998018484A1 (en) | 1998-05-07 |
| DE69739332D1 (en) | 2009-05-07 |
| PT1743650E (en) | 2009-06-25 |
| EP0875251B1 (en) | 2006-12-13 |
| EP0875251A1 (en) | 1998-11-04 |
| JP3845915B2 (en) | 2006-11-15 |
| JPH10130165A (en) | 1998-05-19 |
| ES2323326T3 (en) | 2009-07-13 |
| PT875251E (en) | 2007-01-31 |
| EP1743650A3 (en) | 2007-03-21 |
| DE69737088T2 (en) | 2007-04-12 |
| EP1743650B1 (en) | 2009-03-25 |
| CA2638985A1 (en) | 1998-05-07 |
| DE69737088D1 (en) | 2007-01-25 |
| CA2638985C (en) | 2011-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU688214B2 (en) | Method for treatment of autoimmune diseases using interferon-TAU | |
| DE69333321T3 (en) | Use of a consensus interferon to reduce side effects in the interferon treatment of viral hepatitis. | |
| JPH03193736A (en) | Therapeutic composition for treating leukemia characterized by polypeptide contained therein and having activity of human interleukin 2 | |
| CA2241941C (en) | Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis | |
| DE60216458T2 (en) | METHOD FOR TRIGGERING A CONTINUOUS IMMUNE RESPONSE | |
| US5250296A (en) | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine | |
| US5178855A (en) | Treatment of luekocyte dysfunction with GM-CSF | |
| US5466447A (en) | Method for treating psoriasis | |
| CZ120298A3 (en) | Use of protein obtained from chemokin of mammals | |
| NZ298432A (en) | Therapeutic use of a lysozyme dimer for the treatment of cancer, hair loss and fish and bee diseases | |
| JP3631245B2 (en) | Use of hymenoptera venom for the manufacture of a medicament for the treatment of DNA virus infection | |
| US5268169A (en) | Treatment method of ovarian cancer using interferon gamma | |
| JP2784401B2 (en) | How to treat chronic myeloid leukemia | |
| JP3962097B2 (en) | Relief of side effects caused by immunosuppressants | |
| KR100266929B1 (en) | Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof. | |
| JPH06340549A (en) | Therapeutic agent for feline respiratory organ disease and therapeutic method using the therapeutic agent | |
| EP0262802A2 (en) | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus | |
| CA2188871C (en) | Method for treating psoriasis | |
| US6350443B1 (en) | Method of treatment for feline leukemia virus infections | |
| JPH11130693A (en) | Medicine for feline aids viral infectious disease and its treatment | |
| JP3348851B2 (en) | Pharmaceutical pentapeptide compositions and methods of use | |
| EP0405463A2 (en) | Supporting agents for anti-cancer therapy | |
| AU632528B2 (en) | Use of certain gamma interferons in the preparation of pharmaceutical compositions intended for the treatment of cancer of the ovary by intra-peritoneal route | |
| EP0619120B1 (en) | Use of human interferon-alpha for the manufacture of a medicament for treatment of respiratory disease in cats | |
| McWhorter et al. | Conservative management for a patient with aplastic anemia without use of blood products. Case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20171030 |